In an interview with Applied Clinical Trials Associate Editor Don Tracy, Richard Young, CEO, CluePoints, discusses goals of the SCOPE Summit and CluePoints' evolving approach to risk detection.

While death rates from cardiovascular disease have declined 60% since 1950, a recent upward trend aligns with increases in ...

Following the president’s recent executive order dismantling diversity, equity, and inclusion policies, the main page for the ...

The American Gastroenterology Association (AGA) updated its clinical practice guidelines for managing hepatitis B ...

Clinical data management companies play a crucial role in the healthcare sector by ensuring the accurate collection, ...

Losing and regaining weight repeatedly—a pattern known as yo-yo dieting or body-weight cycling—can significantly increase the ...

To avoid a tug-of-war between scientific rigour and operational efficiency, we must focus on the user and data journeys of ...

A systematic review and meta-analysis estimating the differences in bleeding risks between therapeutic-dose non-vitamin K oral anticoagulants (NOACs) and single antiplatelet therapy (aspirin) found ...

Following clinical protocols and care pathways will enable a more controlled and safe ... The automation of the ED is a solution to build robust risk management process by utilising and analysing the ...

Blackstone Life Sciences and Anthos Therapeutics, Inc. (“Anthos” or the “company”), a transformative, clinical-stage biopharmaceutical company developing innovative therapies for the treatment of ...